Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
26. |
ECCT/19/03/01 | Validation of syringe extension device Validation of re-usable, low cost syringe extension device for the provision of paracervical analgesia during gynecological procedures |
Principal Investigator(s) 1. Stephen Gwer 2. Aparna Ramanathan Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 2. Kisumu County Hospital (Kisumu county) 3. God\'s Will Clinic (Kisumu county) 4. Marie Stopes Kenya-Kisumu Clinic (Kisumu county) |
View |
27. |
ECCT/19/05/01 | A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults |
Principal Investigator(s) 1. Omu Anzala Site(s) in Kenya KAVI-ICR KNH SITE |
View |
28. |
ECCT/19/08/01 | Use of malaria infection by injection to study malaria transmission Safety and feasibility of a malaria transmission model in semi-immune Kenyan adults using Plasmodium falciparum sporozoites |
Principal Investigator(s) 1. Melissa Kapulu 2. Philip Bejon Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
29. |
ECCT/19/11/03 | A Pilot BE study for Enalpril 5mg A bioequivalent pilot study of a locally-produced brand of enalapril tablets: a key step towards implementation of bioequivalent study regulatory requirements in East Africa |
Principal Investigator(s) 1. Simon Njoroge Njenga Site(s) in Kenya Kenya Medical Research Institute |
View |
30. |
ECCT/20/05/01 | ChAdOx1 nCoV-19 trial A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI-CGMRC |
View |